Successful Treatment of Polymicrobial Calcaneal Osteomyelitis

SUGAR LAND, TX – Multidrug-resistant osteomyelitis was successfully treated with telavancin, rifampin, and meropenem, as published in an article in The Annals of Pharmacotherapy. Primary author was Mary Beth Brinkman, a research student at the time with Healix®, in collaboration with Kaili Fan, MD, treating physician; Renee L. Shiveley, PharmD, clinical pharmacist; and Lucinda J. Van Anglen, PharmD, Vice President of Pharmacy, Healix.

Antimicrobial selection for osteomyelitis infections presents a challenge to the clinician due to patient intolerance, increasing antimicrobial resistance, and variable antimicrobial penetration at the site of infection. This is the first case report of the successful use of a regimen including telavancin for the treatment of a recurrent, coagulase-negative Staphylococcus osteomyelitis infection.

An 18-year-old male with spina bifida was treated primarily in the outpatient setting over the course of 133 days with multiple antimicrobials for a recurrent right calcaneal wound and osteomyelitis infection. Initial cultures were positive for methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus, which were treated with intravenous vancomycin 1 g every 12 hours, increased after 13 days to 1.5 g every 12 hours with addition of rifampin 300 mg twice daily, both of which were discontinued on day 22 due to leukopenia (white blood cell count 3.0 × 103/μL) and neutropenia (absolute neutrophil count 0.2 × 103/μL). Daptomycin 8 mg/kg/day was then initiated with rifampin 300 mg twice daily; treatment was discontinued after 49 days due to an elevated creatine kinase level of 1831 U/L (baseline 86). Intravenous meropenem 1 g every 8 hours was again initiated on day 83 following additional identification of quinolone-resistant Pseudomonas aeruginosa from the soft tissue of the right foot. Intravenous vancomycin 1 g every 12 hours was also restarted at this time for persistent coagulase-negative Staphylococcus and oral rifampin 300 mg twice daily was again added. Adverse events again required the discontinuation of vancomycin on day 91. The eventual drug therapy regimen consisted of telavancin 750 mg/day for 42 days, meropenem for 50 days, and oral rifampin for 50 days. At the end of treatment, the patient’s right heel wound had almost completely closed. He was without recurrence or treatment-related adverse events at follow-up one year later.

In this complex case involving a polymicrobial infection of the right calcaneal bone and surrounding soft tissue, receiving eventual drug therapy including telavancin, meropenem, and rifampin, resulted in a successful clinical response.

Brinkman MB, Fan K, Shiveley, RL, Van Anglen, LJ. Successful Treatment of Polymicrobial Calcaneal Osteomyelitis with Telavancin, Rifampin, and Meropenem. Ann Pharmacother. 2012; 46(6):e15. DOI: 10.1345/aph.1Q331.

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.